Trans-vitreal endoresection for vasoproliferative retinal tumours.
We present an interventional consecutive case series to describe our experience of transvitreal endoresection (TVE) for vasoproliferative retinal tumours (VPRTs). Three patients with VPRTs refractory to conventional treatment modalities of cryotherapy, plaque radiotherapy and anti-VEGF presented with macular exudative changes and were offered TVE. Complete ophthalmic examination with colour fundal photographs was performed before and during the follow-up period. All patients were followed up for 6 months following silicone oil removal. At the last follow up, resolution of macular and retinal exudative changes with parallel improvement in vision was observed. No recurrences were detected during the follow-up period. Two of three patients had simultaneous cataract surgery and developed fibrinous uveitis, requiring management with intensive topical steroids. After 3 months, these patients had a fibrotic pupillary membrane enveloping the intraocular lens (IOL) with posterior synechiae. These two patients underwent SO removal, IOL explantation and artisan IOL (iris clipped) insertion, resulting in visual improvement. We did not observe any PVR complications in our cases. TVE represents an effective and safe option for the treatment of VPRTs refractory to other treatment modalities. Further studies with a larger sample size and long-term follow up are indicated to evaluate the role of TVE in the management of VPRTs.
Gibran
Syed K
SK
Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX 77555-1106, USA. syedgibran@yahoo.com
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001918:Brachytherapy; D002386:Cataract / Q000150:complications; D002387:Cataract Extraction / Q000009:adverse effects; D017679:Cryotherapy; D005122:Exudates and Transudates; D005260:Female; D006391:Hemangioma / Q000150:complications / Q000601:surgery* / Q000628:therapy; D006801:Humans; D008297:Male; D019572:Retinal Neoplasms / Q000150:complications / Q000601:surgery* / Q000628:therapy; D014606:Uveitis, Anterior / Q000209:etiology; D014786:Vision Disorders / Q000209:etiology; D018630:Vitreoretinopathy, Proliferative / Q000209:etiology / Q000517:prevention & control; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab